8C5 Panoramica delle azioni Coherus BioSciences, Inc. è una società biofarmaceutica che si concentra sulla ricerca, lo sviluppo e la commercializzazione di trattamenti antitumorali principalmente negli Stati Uniti. Maggiori dettagli
Premi Analisi del rischio + 1 più rischio
Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Coherus BioSciences, Inc. Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Coherus BioSciences Prezzi storici delle azioni Prezzo attuale dell'azione US$1.41 Massimo di 52 settimane US$3.34 Minimo di 52 settimane US$0.61 Beta 0.86 Variazione di 1 mese 17.22% Variazione a 3 mesi 52.83% Variazione di 1 anno -52.74% Variazione a 3 anni -89.88% Variazione a 5 anni -90.66% Variazione dall'IPO -88.03%
Notizie e aggiornamenti recenti
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carinoma at ASCO-GI 2025 Dec 19 Intas Pharmaceuticals Limited entered into asset purchase agreement to acquire UDENYCA Franchise of Coherus BioSciences, Inc. (NasdaqGM:CHRS) for $560 million. Dec 04
New major risk - Revenue and earnings growth Nov 16
No longer forecast to breakeven Nov 08
Coherus BioSciences, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 31
New minor risk - Market cap size Oct 18 Vedi altri aggiornamenti
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carinoma at ASCO-GI 2025 Dec 19 Intas Pharmaceuticals Limited entered into asset purchase agreement to acquire UDENYCA Franchise of Coherus BioSciences, Inc. (NasdaqGM:CHRS) for $560 million. Dec 04
New major risk - Revenue and earnings growth Nov 16
No longer forecast to breakeven Nov 08
Coherus BioSciences, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 31
New minor risk - Market cap size Oct 18
Forecast breakeven date pushed back to 2025 Aug 11
Second quarter 2024 earnings released: US$0.11 loss per share (vs US$0.49 loss in 2Q 2023) Aug 09
Coherus BioSciences, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Aug 01
New major risk - Share price stability Jul 02
Coherus BioSciences, Inc. Appoints Rita Karachun to Its Board of Directors Jun 06
Coherus Biosciences, Inc. Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-Chemokine Receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting May 24
Forecast breakeven date moved forward to 2024 May 12
First quarter 2024 earnings released: EPS: US$0.91 (vs US$0.95 loss in 1Q 2023) May 10 Coherus BioSciences, Inc. announced that it has received $38.7 million in funding May 10
Coherus BioSciences, Inc. Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI®? (toripalimab-tpzi) with ENB-003 for the Treatment of Ovarian Cancer May 09
Coherus BioSciences, Inc. to Report Q1, 2024 Results on May 09, 2024 May 03
Coherus BioSciences, Inc. Announces Presentation of Clinical Data for CHS-114 at 2024 American Society of Clinical Oncology Annual Meeting Apr 24
Coherus BioSciences, Inc., Annual General Meeting, May 29, 2024 Apr 16
Full year 2023 earnings released: US$2.53 loss per share (vs US$3.76 loss in FY 2022) Mar 14
Forecast breakeven date pushed back to 2026 Mar 14
Coherus BioSciences, Inc. to Report Q4, 2023 Results on Mar 13, 2024 Mar 06
New major risk - Financial position Feb 28
Coherus BioSciences, Inc. Announces U.S. Launch of UDENYCA ONBODY a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv Feb 22 Sandoz Group AG (SWX:SDZ) entered into a definitive agreement to acquire CIMERLI an ophthalmology franchise from Coherus BioSciences, Inc. (NasdaqGM:CHRS) for approximately $170 million. Jan 22
Coherus BioSciences, Inc. Presents Positive Phase 2 Clinical Data on Casdozokitug, A First-In-Class IL-27-Targeted Antibody, At the 2024 ASCO GI Cancers Symposium Jan 19
Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv Dec 27 Coherus BioSciences, Inc. Appoints Bryan McMichael as Principal Financial Officer
Coherus BioSciences, Inc. Announces Resignation of McDavid Stilwell as Chief Financial Officer, Effective December 31, 2023 Dec 08
Coherus BioSciences, Inc. Presents Phase 1/2 Clinical Data on Casdozokitug at the 2023 ESMO Immuno-Oncology Congress Dec 06
Coherus and Junshi Biosciences Announces Publication of Positive Final Overall Survival Results of Jupiter-02, A Phase 3 Trial Evaluating Loqtorzi (Toripalimab-Tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association Nov 29 Coherus Biosciences, Inc. Lowers Its Revenue Guidance for 2023 Nov 08
Third quarter 2023 earnings released: US$0.41 loss per share (vs US$1.12 loss in 3Q 2022) Nov 07 Coherus BioSciences, Inc. to Report Q3, 2023 Results on Nov 06, 2023
Coherus Biosciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Biosciences Announce FDA Approval of Loqtorzi (Toripalimab-Tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma Oct 28
Coherus BioSciences, Inc. Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Oct 16
Coherus Biosciences, Inc. Announces Resubmission of Biologics License Application (Bla) Supplement for Udenyca(R) Onbody Oct 06
FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus BioSciences, Inc Also Announces Completion of Toripalimab FDA Inspections Sep 26
Coherus BioSciences, Inc. (NasdaqGM:CHRS) completed the acquisition of Surface Oncology, Inc. (NasdaqGM : SURF) from Novartis Institutes for BioMedical Research, Inc., Atlas Venture Fund IX, L.P., managed by Atlas Venture L.P., ARK Investment Management LLC, EcoR1 Capital, LLC and others. Sep 09
Second quarter 2023 earnings released: US$0.49 loss per share (vs US$0.65 loss in 2Q 2022) Aug 03
Coherus Biosciences, Inc. Provides Revenue Guidance for the Year 2023 Aug 03
Coherus BioSciences, Inc. to Report Q2, 2023 Results on Aug 02, 2023 Jul 28
Coherus Biosciences, Inc. Announces Appointment of Michael Ryan to Board of Directors Jul 23
Coherus Launches Yusimry™, A Biosimilar of Humira® Jul 04 Coherus BioSciences, Inc. (NasdaqGM:CHRS) entered into a definitive merger agreement to acquire Surface Oncology, Inc. (NasdaqGM : SURF) for transaction value of $65 million. Jun 18
Coherus BioSciences, Inc. has completed a Follow-on Equity Offering in the amount of $50.000001 million. May 18
Coherus BioSciences, Inc. has completed a Follow-on Equity Offering in the amount of $50.000001 million. May 17
Coherus BioSciences, Inc. Provides Earnings Guidance for the Full Year 2023 May 10
First quarter 2023 earnings released: US$0.95 loss per share (vs US$1.24 loss in 1Q 2022) May 09
Full year 2022 earnings released: US$3.76 loss per share (vs US$3.81 loss in FY 2021) Mar 08
Shanghai Junshi Biosciences Co., Ltd and Coherus Biosciences, Inc. Announce Positive Results of A Final Analysis of Overall Survival from the Pivotal Study JUPITER-02 Feb 16
Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma Dec 26
High number of new and inexperienced directors Nov 16
Third quarter 2022 earnings released: US$1.12 loss per share (vs US$0.49 loss in 3Q 2021) Nov 10
Coherus BioSciences, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Nov 02
Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc. Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical Oncology Oct 13
Coherus to Launch Cimerli (Ranibizumab-Eqrn) in the United States on October 3, 2022 Sep 20
Coherus BioSciences, Inc. Announces Executive Changes Sep 10
Second quarter 2022 earnings released: US$0.65 loss per share (vs US$0.40 loss in 2Q 2021) Aug 05
FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability Exclusivity Aug 03
Coherus BioSciences, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 29
Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma Jul 07
Coherus BioSciences Appoints Jill O’Donnell-Tormey to Its Board of Directors, Nominating and Corporate Governance Committee of the Board of Directors May 12
First quarter 2022 earnings released: US$1.24 loss per share (vs US$2.38 loss in 1Q 2021) May 07
Coherus Biosciences, Inc. Appoints Charlie Newton to Board of Directors, Member of Audit Committee May 06
Coherus BioSciences, Inc. to Report Q1, 2022 Results on May 05, 2022 May 02
High number of new and inexperienced directors Apr 27
Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting Apr 09
Coherus BioSciences, Inc., Annual General Meeting, May 17, 2022 Apr 05
Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Announce Positive Results from Phase 3 Esophageal Cancer Study of Toripalimab Published in Cancer Cell Mar 06
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Feb 18
Coherus BioSciences, Inc. Appoints Paul Reider as Chief Commercial Officer Feb 16
Coherus BioSciences, Inc. to Report Q4, 2021 Results on Feb 17, 2022 Feb 12
Coherus BioSciences, Inc. Announces Management Changes Feb 08
Coherus BioSciences, Inc. Announces U.S. FDA Approval of YUSIMRY Dec 21
Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc. Announce Positive Interim Overall Survival Results of CHOICE-01, A Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer Dec 15
Third quarter 2021 earnings released: US$0.49 loss per share (vs US$0.39 profit in 3Q 2020) Nov 09
Positive Interim Results of CHOICE-01 Study Evaluating Coherus' and Junshi Biosciences’ Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer Sep 15
Shanghai Junshi Biosciences Co., Ltd. and Coherus Biosciences, Inc. Announce Completion of Rolling BLA Submission to U.S. FDA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma Sep 02
Shanghai Junshi Biosciences Co., Ltd. and Coherus Biosciences, Inc. Announce Positive Interim Results from the Pivotal Study Choice-01 Aug 20
Junshi Biosciences and Coherus Announce U.S. FDA Breakthrough Therapy Designation Granted for Toripalimab for 1st Line Treatment of Nasopharyngeal Carcinoma Aug 13
Independent Director Mary Szela has left the company Aug 12
Second quarter 2021 earnings released: US$0.40 loss per share (vs US$0.83 profit in 2Q 2020) Aug 08 Rendimenti per gli azionisti 8C5 DE Biotechs DE Mercato 7D 3.1% 2.1% 0.6% 1Y -52.7% -13.8% 7.2%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: 8C5 ha avuto una performance inferiore rispetto al German Biotechs che ha registrato un rendimento -13.8 % nell'ultimo anno.
Rendimento vs Mercato: 8C5 ha avuto una performance inferiore al mercato German che ha registrato un rendimento 7.2 % nell'ultimo anno.
Volatilità dei prezzi Is 8C5's price volatile compared to industry and market? 8C5 volatility 8C5 Average Weekly Movement 25.0% Biotechs Industry Average Movement 7.1% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.7% 10% least volatile stocks in DE Market 2.4%
Prezzo delle azioni stabile: Il prezzo delle azioni di 8C5 è stato volatile negli ultimi 3 mesi.
Volatilità nel tempo: La volatilità settimanale di 8C5 è aumentata da 16% a 25% nell'ultimo anno.
Informazioni sull'azienda Fondato I dipendenti AMMINISTRATORE DELEGATO Sito web 2010 235 Denny Lanfear www.coherus.com
Coherus BioSciences, Inc. è una società biofarmaceutica che si concentra sulla ricerca, lo sviluppo e la commercializzazione di trattamenti antitumorali principalmente negli Stati Uniti. L'azienda sviluppa UDENYCA, un biosimilare di Neulasta, un fattore stimolante le colonie di granulociti a lunga durata d'azione; LOQTORZI, un nuovo inibitore di PD-1; e Casdozokitug, un anticorpo monoclonale ricombinante umano isotipo G1 (IgG1), in fase di sperimentazione, che ha come bersaglio l'interleuchina 27. L'azienda sta inoltre sviluppando CHS-114, un farmaco altamente sperimentale e di alto livello che ha come obiettivo il trattamento del cancro.
Mostra di più Coherus BioSciences, Inc. Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Coherus BioSciences con la sua capitalizzazione di mercato? 8C5 statistiche fondamentali Capitalizzazione di mercato €165.04m Guadagni(TTM ) -€432.63k Ricavi(TTM ) €292.59m
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) 8C5 Conto economico (TTM ) Ricavi US$304.34m Costo del fatturato US$168.26m Profitto lordo US$136.08m Altre spese US$136.53m Guadagni -US$450.00k
Ultimi guadagni dichiarati
Sep 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) -0.0039 Margine lordo 44.71% Margine di profitto netto -0.15% Rapporto debito/patrimonio netto -300.7%
Come si è comportato 8C5 nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2024/12/30 01:47 Prezzo dell'azione a fine giornata 2024/12/30 00:00 Guadagni 2024/09/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Coherus BioSciences, Inc. è coperta da 17 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Colleen Kusy Baird Balaji Prasad Barclays Balaji Prasad Barclays
Mostra 14 altri analisti 
